A combination comprising camptothecin and a stilbene derivative for the treatment of cancer

Details for Australian Patent Application No. 2002216029 (hide)

International Classifications

Event Publications

5 January 2006 Application Accepted

Published as AU-B-2002216029

2 February 2006 Assignment before Grant

Aventis Pharma S.A. The application has been assigned to Pfizer, Inc.

4 May 2006 Standard Patent Sealed

21 May 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.